FDA Approves Alzheimer's Drug

Approval gives hope to the field, though important questions remain

Biogen's aducanumab drug trials were prematurely discontinued, so the conditional approval June 7 by the U.S. Food and Drug Administration has been met with mixed reactions in the field. Experts eagerly await results from ongoing trials of other amyloid-plaque reducing drugs in the next one to three years to know with greater certainty whether removal of amyloid plaques has a clinical benefit. 

Better Brain Health

7 Building Blocks to Aging Well

June is Alzheimer's and Brain Health Awareness Month. Join us on our series of building blocks that will guide you along a path of awareness, giving you the tools you need for successful aging. We also highlight three common concerns you may have with making healthy lifestyle changes, and seek advice from Banner Health medical experts to get you started today.

Learn More.